Table 1

Associations of TA genotypes with features of breast cancer

FeaturesTotal patientsNo. of patients (%)P
(TA)0(TA)0/(TA)9, (TA)9
Age (yr)
<453523 (24.5)12 (25.5)
45–553622 (23.4)14 (29.8)0.65a
>557049 (52.1)21 (44.7)
Tumor size (cm)
<24026 (28.3)14 (30.4)0.47b
≥29866 (71.7)32 (69.6)
Nodal status
Negative5231 (34.8)21 (45.6)0.10b
Positive8358 (65.2)25 (54.4)
Gradec
I–II6144 (65.7)17 (53.1)0.16b
III3823 (34.3)15 (46.9)
Histology
Ductal9865 (69.2)33 (70.2)
Lobular1912 (12.7)7 (14.9)0.86a
Other2417 (18.1)7 (14.9)
Staged
I4223 (24.7)19 (40.4)
II8055 (59.2)25 (53.2)0.079a
III–IV1815 (16.1)3 (6.4)
ER statuse
Negative4631 (34.4)15 (31.9)0.46b
Positive9159 (65.6)32 (68.1)
PR statuse
Negative5031 (34.4)19 (41.3)0.27b
Positive8659 (65.6)27 (58.7)
PSA statusf
Negative11985 (91.4)34 (72.3)0.004b
Positive218 (8.6)13 (27.7)
Adjuvant treatment
None4126 (27.7)15 (31.9)
Tamoxifen6546 (48.9)19 (40.4)0.63a
Chemotherapy± tamoxifen3522 (23.4)13 (27.7)
  • a χ2 test.

  • b Fisher’s exact test.

  • c Bloom-Richardson grading system.

  • d TNM system.

  • e Cutoff point: 10 fmol/mg protein.

  • f Cutoff point: 60 ng/g protein, equal to the 75th percentile of the distribution of PSA concentrations.